IL2 and glioma: In a clinical trial conducted in 2004 [106], autologous NK cells co-cultured with an irradiated human feeder cell line (HFWT) using RHAM-alpha medium supplemented with 5% autologous plasma and IL-2 were injected in nine adult recurrent-glioma patients.